Sonnet Biotherapeutics company info

What does Sonnet Biotherapeutics do?
Sonnet Biotherapeutics (NASDAQ:SONN) is a biopharmaceutical company engaged in developing innovative therapies with a focus on oncological and immunological conditions. Leveraging its proprietary Fully Human Albumin Binding (F H AB) technology, Sonnet aims to create biologic drugs with enhanced efficacy and reduced toxicity, providing new treatment options for patients suffering from severe diseases. The company is committed to advancing its pipeline through rigorous scientific research, strategic collaborations, and clinical development programs. Its objective is to address unmet medical needs by bringing forth novel therapeutics that can offer meaningful improvements in patients' lives.
Sonnet Biotherapeutics company media
Company Snapshot

Is Sonnet Biotherapeutics a public or private company?

key
Ownership
Public

How many people does Sonnet Biotherapeutics employ?

people
Employees
12

What sector is Sonnet Biotherapeutics in?

pie chart
Sector
Health Care

Where is the head office for Sonnet Biotherapeutics?

location pin
Head Office
Charlotte, United States

What year was Sonnet Biotherapeutics founded?

founded flag
Year Founded
1999
What does Sonnet Biotherapeutics specialise in?
/Cancer Therapies /Biopharmaceutical Research /Drug Development /Oncology Focus /Therapeutic Platforms /Clinical Trials

What are the products and/or services of Sonnet Biotherapeutics?

Overview of Sonnet Biotherapeutics offerings
SON-1010 (IL-12Fc): A fusion protein for cancer treatment, leveraging interleukin-12 to boost the immune system's ability to fight tumors.
SON-1210 (IL-15Fc): Focuses on enhancing the body's natural killer (NK) and T cells' capabilities against cancer through an interleukin-15 fusion protein.
SON-081 (Low Dose IL-6): Developed for the treatment of peripheral neuropathy, specifically targeting diabetic peripheral neuropathy through low dose interleukin-6.
SON-080 (Low Dose IL-6): Aimed at treating chemotherapy-induced peripheral neuropathy, utilizing a low dose of interleukin-6 to mitigate symptoms.
Bispecific Antibody Therapies: Innovative therapies combining two different antibodies to target multiple cancer pathways simultaneously.
Immunotherapy Platforms: Advanced technology platforms designed to enhance the development of next-generation immunotherapies for cancer.

Who is in the executive team of Sonnet Biotherapeutics?

Sonnet Biotherapeutics leadership team
  • Dr. Pankaj  Mohan Ph.D.
    Dr. Pankaj Mohan Ph.D.
    Founder, Chairman, CEO & President
  • Dr. John K. Cini Ph.D.
    Dr. John K. Cini Ph.D.
    Chief Scientific Officer & Co-Founder
  • Mr. Jay  Cross
    Mr. Jay Cross
    Chief Financial Officer
  • Mr. Donald J. Griffith CPA, CPA
    Mr. Donald J. Griffith CPA, CPA
    Controller & Director
  • Ms. Susan  Dexter
    Ms. Susan Dexter
    Chief Technical Officer
  • Dr. Richard T. Kenney FACP, M.D.
    Dr. Richard T. Kenney FACP, M.D.
    Chief Medical Officer
  • Mr. Manuel  Dafonseca
    Mr. Manuel Dafonseca
    Head of Clinical Operations